Navigation Links
ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
Date:12/6/2011

h the Securities and Exchange Commission for the periods ended March 31, 2011, June 30, 2001 and September 30, 2011, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release are made as of the date hereof and may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. These forward looking statements should not be relied upon as representing our assessments as of any date subsequent to the date of this press release.

Halozyme Safe Harbor Statement

 In addition to historical information, the statements set forth above regarding the subcutaneous Cinryze with rHuPH20 product candidate, its possible advantages and attributes,  the anticipated presentation of the complete data from the initial Phase 2 trial referenced in this press release, future clinical trials plans, including the anticipated Phase 2 dose ranging efficacy combination trial, and other statements regarding Halozyme's product candidates and potential attributes of these product candidates, involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning.  Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including clinical trial results, delays in development, possible adverse events associated with the use of the product candidate, regulatory delays and competitive conditions. These and other factors that may result in differences are discussed in greater de
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ViroPharma to Participate in Two November Healthcare Investor Conferences
2. ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
3. ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
4. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
5. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
6. ViroPharma Announces Additional Securities Repurchase Program
7. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
8. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
9. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
10. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
11. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number ... lead compound, LB‑100, is being conducted, has been expanded from ... , M.D., the founder and President of Lixte, said that, ... single site. Accrual of patients, however, was slower than projected. ...
(Date:1/23/2015)... CAPE TOWN, South Africa , Jan. 23, 2015 ... and distributor of personal protective equipment for all forms ... include the flagship Leatt-Brace® neck brace, announced today that ... minicross racing federation, now requires all riders to wear ...
(Date:1/23/2015)... (NYSE: MNK ) announced today that its ... The open-ended authorization permits the company to repurchase up ... "Funding additional initiatives and seeking attractive business ... pursue a range of focused growth strategies," said ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
...  VIVUS, Inc. (NASDAQ: VVUS ) today announced ... Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing ... in adults. The Committee voted 20 to 2, on the recommendation ... "We are pleased with the panel,s approval ...
... 21, 2012  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ... conferences: , Citi 2012 Global Healthcare Conference at ... , RBC Capital Markets, Healthcare Conference at 9:00 ... The sessions may be accessed through the Company,s ...
Cached Medicine Technology:FDA Advisory Committee Recommends Approval of Qnexa® 2FDA Advisory Committee Recommends Approval of Qnexa® 3FDA Advisory Committee Recommends Approval of Qnexa® 4FDA Advisory Committee Recommends Approval of Qnexa® 5Regeneron Announces February 2012 Investor Conference Presentations 2
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... annual revenues in the past three years. Today, the business ... , According to the sales manager of the company, this ... in 2015. This point can be reflected on the discounted ...
(Date:1/22/2015)... years since the release of their debut recording Love is King, ... & Matthew Love – the duo are pleased to announce their ... Swan Records on February 24, 2015. , THE ROAD offers the ... all of us to walk out of the mire of our ...
(Date:1/22/2015)... 22, 2015 EBSCO Information Services ... expanding their relationship in an effort to further promote visibility ... While EBSCO has long made AMA journals available via its ... for The JAMA Network. , Long known as ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for ... its latest collection of wedding dresses , and launches ... is the wedding dress on your big day; the wedding ... Every bride wants to find the most suitable wedding dress. ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining ... for reducing the costs of an auto insurance policy . ... to get lower prices for their vehicle insurance policies. The safety ... determining policy costs. Because of this, drivers should always carry ...
Breaking Medicine News(10 mins):Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... for the painful growths called gallstones has been removal ... patented in China, promises to make removing the entire ... People,s Hospital of Panyu District and Central South University ... locating and clearing out gallstones and other gallbladder lesions. ...
... -- Middle-aged men with blood pressure in the upper-normal range ... researchers say. Atrial fibrillation -- which affects more ... that can lead to stroke and other heart-related complications. High ... Previous research has shown that women with blood pressure ...
... New York, NY (January 17, 2012) Researchers at ... early cellular and molecular events that give rise to ... fastest-rising solid tumor in the United States. The findings, ... conventional wisdom regarding the origin and development of this ...
... News) -- A process linked to natural cell aging has ... Telomeres -- lengths of DNA on the ends of chromosomes, ... shoelace tip -- naturally shorten with age, but can also ... been found in some types of cancer and preliminary research ...
... rap in past research studies, being labeled the group ... But a researcher from the Mandel School of Applied ... findings in a new studydemonstrating that inmates with severe ... than those with substance abuse issues or no mental ...
... release is available in German . What ... is immobile for two weeks? This is the question addressed in ... Surgery Department at Zurich University Hospital. For the study, ten right-handed ... plaster or sling, the test people,s right hands were restricted to ...
Cached Medicine News:Health News:'Upper Normal' Blood Pressure Linked to Heart Risk in Men 2Health News:Study reveals origins of esophageal cancer 2Health News:Study reveals origins of esophageal cancer 3Health News:Knee Arthritis May Speed Up Process Linked to Cell Aging 2Health News:Mental illness protects some inmates from returning to jail 2Health News:Arm in plaster changes brain in 16 days 2
Barraquer needle holder, curved, delicate....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Rhoton #12 straight point needle semisharp, titanium....
Micro 2000, micro scissors micro 2000 supercut....
Medicine Products: